Dose Optimization of Pembrolizumab: Less May Be More

Clin Pharmacol Ther. 2022 May;111(5):993. doi: 10.1002/cpt.2490. Epub 2021 Dec 1.

Authors

Mark J Ratain¹, Cody J Peer², William D Figg², Daniel A Goldstein^{3

4

5}

Affiliations

¹ Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA.
² Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.
³ Tel Aviv University, Tel Aviv, Israel.
⁴ Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
⁵ Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.

PMID: 34854077
DOI: 10.1002/cpt.2490

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized*
Antineoplastic Agents, Immunological* / adverse effects
Antineoplastic Combined Chemotherapy Protocols
Humans

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab